What is Twist Bioscience?
Twist Bioscience is a leading synthetic biology company that specializes in the high-precision, large-scale manufacturing of synthetic DNA. Leveraging a proprietary silicon-based platform, the company empowers researchers across life sciences, medicine, agriculture, and industrial biotechnology to accelerate innovation. Its core offerings facilitate advanced genetic research, drug discovery, and the development of sustainable solutions by providing reliable, high-quality DNA at scale. The company's technology is instrumental in driving progress in areas such as genomics, synthetic genomics, and personalized medicine, positioning it at the forefront of biological innovation.
How much funding has Twist Bioscience raised?
Twist Bioscience has raised a total of $728.7M across 14 funding rounds:
Multiple Rounds
$50.2M
Series C
$37M
Series D
$61M
Debt
$20M
Series E
$60M
Share Placement
$50M
Stock Offering
$69M
Stock Offering
$84.1M
Multiple Rounds
$297.4M
Series A (2014): $9.1M with participation from Undisclosed
Series B (2014): $26M led by Paladin Capital Group, Tao Invest, Yuri Milner, and ARCH Venture Partners
Grant (2014): $5.1M supported by DARPA
Debt (2014): $10M featuring Silicon Valley Bank
Series C (2015): $37M backed by Fidelity Management & Research Company, Yuri Milner, ARCH Venture Partners, Tao Invest, Foresite Capital Management, Illumina Inc., and Paladin Capital Group
Series D (2016): $61M with participation from Yuri Milner, Cormorant Asset Management, ARCH Overage Fund, ARCH Venture Partners, Foresite Capital Management, Paladin Capital Group, Boris Nikolic, WuXi Healthcare Ventures, Merieux Development, Illumina Inc., Tao Invest, and Fidelity Management & Research Company
Debt (2016): $20M led by Silicon Valley Bank
Series E (2017): $60M supported by KANGMEI Group, NFT Investment Limited, Reinet Fund, Ditch Plains Capital Management, 3W Partners Capital, Bay City Capital, Biomatics Capital, and FIS Global
Share Placement (2018): $50M featuring Undisclosed
Stock Issuance/Offering (2018): $69M backed by Undisclosed
Stock Issuance/Offering (2019): $84.1M with participation from Undisclosed
Stock Issuance/Offering (2020): $50M led by Undisclosed
Stock Issuance/Offering (2020): $140M supported by Undisclosed
Stock Issuance/Offering (2020): $107.4M featuring Undisclosed
Key Investors in Twist Bioscience
ARCH Venture Partners
ARCH Venture Partners is a premier venture capital firm focused on early-stage life sciences and advanced technology companies. They actively co-found startups with scientists and entrepreneurs, commercializing innovations from academic and corporate research.
Foresite Capital Management
Foresite Capital is a multi-stage investment firm dedicated to transforming healthcare and life sciences through investments in companies leveraging biology and big data. They focus on breakthrough opportunities at the intersection of technology and biotechnology.
Paladin Capital Group
Paladin Capital Group is a global multi-stage investment firm specializing in venture capital and growth financing. They strategically deploy capital to support and scale companies across various development stages, emphasizing hands-on partnership and value creation.
What's next for Twist Bioscience?
With a history of significant capital infusions, including major enterprise-level funding and strategic investments, Twist Bioscience is well-positioned for continued growth and innovation. The company's trajectory suggests a focus on scaling its manufacturing capabilities, expanding its product portfolio, and forging strategic partnerships to further penetrate key markets. Future developments are likely to involve advancements in DNA synthesis technology, applications in novel therapeutic areas, and contributions to the burgeoning field of synthetic biology, solidifying its leadership in the industry.
See full Twist Bioscience company page
